The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...

The percentage of overweight or obese adults prescribed GLP-1s jumped by almost 587% between 2019 and 2024, according to a ...

Every healthcare company claims to be working in the patient's best interest, and yet prices only seem to rise.

UBS analyst AJ Rice reaffirmed a “Buy” rating on The Cigna Group (NYSE:CI) with a price target of $390. Rice shared his views ...

The massive pharmacy middlemen contend that Arkansas’ law, which requires PBMs to divest pharmacies they own in the state, ...

The lower out-of-pocket costs come at a time of governmental scrutiny on prescription drug prices in the US. Evernorth, the health services division of The Cigna Group (NYSE: CI) announced a first ...

Launch prices for self-administered targeted anticancer therapies have grown precipitously,” researchers wrote.

Buying $100 In CI: If an investor had bought $100 of CI stock 15 years ago, it would be worth $929.38 today based on a price ...

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not ...

We came across a bullish thesis on The Cigna Group (CI) on Antonio Linares’ Substack. In this article, we will summarize the ...

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated ...

The Institute for Clinical and Economic Review (ICER) has published its annual report on "unsupported" price increases for medicines that it says have added around $815 million to US drug spending.